🚀In 2024, Amgen took innovation to new heights, with major advances in small cell lung cancer, acute lymphoblastic leukemia, gastric cancer and metastatic colorectal cancer. Amgen’s Sebastien Morisot, Jay Bradner, Brian Lapham and Sumita Bhatta share what these new possibilities mean for patients and how we aim to push boundaries even further in 2025 & beyond. ⬇️
Amgen Oncology
Biotechnology Research
Thousand Oaks, CA 69,223 followers
Committed to the relentless pursuit of breakthroughs for patients with cancer and their families
About us
At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. We have a deep and diverse pipeline of cutting-edge therapeutic approaches that aim to improve outcomes. Amgen has been pursuing novel treatment approaches for more than 40 years, and was the first to commercialize next-generation immuno-oncology therapies. We never stop looking toward the next frontier of innovation to bring the greatest potential benefit to patients. See our Community Guidelines: bit.ly/smcgl See our Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance
- Website
-
http://www.amgenoncology.com
External link for Amgen Oncology
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Thousand Oaks, CA
- Founded
- 1980
Updates
-
🧬B-cell #ALL treatment news: Healio explores the impact of Amgen’s BiTE® immunotherapy for expanded use in the consolidation phase. 🔗https://lnkd.in/g7HXjjeS #AmgenSponsored
-
🧬BiTE® cancer innovation: B-ALL & beyond 🧬 This month, we celebrate 10 years since the first Bispecific T-cell Engager (BiTE®) therapy received global approval – a practice changer for people with B-cell precursor acute lymphoblastic leukemia (B-ALL). Discover how we’re leveraging Amgen’s BiTE® expertise to fight other pervasive and persistent cancers. 🔗 https://amgen.ly/49YyzPy
-
#GastricCancer care is rapidly evolving, with new 🎯targeted options paving the way for personalized care. Discover the FGFR2b research driving new possibilities for metastatic G/GEJ cancer. 🔗Find out more at https://lnkd.in/gqtqzMbC
-
A Decade of Progress & Hope in B-ALL: In celebration of 10 years since the first globally approved BiTE® therapy, WVU Cancer Institute’s Dr. Ashkan Emadi reflects on its impact within the field of oncology, while Mary Ann shares how treatment has brought hope. 🔗Learn more: https://amgen.ly/3VU177g
-
🌟Celebrating 10 years of BiTE® innovation in B-ALL 🌟 For over a decade, Amgen has leveraged patients’ own T cells to target cancer with our Bispecific T-cell Engager (BiTE®) technology. BiTE® science has since evolved how physicians treat B-cell precursor acute lymphoblastic leukemia (B-ALL). On the 10-year anniversary of the global approval of the first BiTE® immunotherapy, Amgen’s Peter Kufer, Byeong Yoon, and Aparna Chavali and WVU Cancer Institute’s Dr. Ashkan Emadi reflect on the development and impact of our groundbreaking therapy. 🔗Read more: https://amgen.ly/4gBGVit
-
🌟New #ALL treatment advances bring us closer to a future where children like MJ – and their families – can embrace hope. 🔗Learn more: https://amgen.ly/4f7UPYw #ASH24
Watch MJ's Story
-
🌟New B-ALL research shared at #ASH24 brings us closer to a future where children like MJ – and their families – can embrace life with renewed confidence and hope. Learn more ⬇️
Chaundra’s son, MJ, was just 8 years old when he was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) – news no parent should ever have to hear and a diagnosis no child should have to face. As a hematologist, I’ve seen how complex and challenging B-ALL can be. But I’ve also seen how research and innovation are transforming the outlook for patients like MJ and their families. Read more about MJ’s journey and the future of B-ALL treatments here: https://lnkd.in/eJdSGyxV #MyCompany #ASH24
-
🩺News from #ASH24: Discover the study results that could impact care for a large number of children newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) – the most common form of cancer in children. 🔗 https://lnkd.in/g9reBHhU
-
We look forward to discussing Children's Oncology Group’s latest Phase 3 data in the most common childhood cancer at #ASH24. This approach could represent a new treatment standard for a large number of children with B-cell precursor acute lymphoblastic leukemia. Find out more below ⬇️
B-ALL NEWS: Today, Amgen announced that Children's Oncology Group will share Phase 3 study results for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL). ➡️ Data from pediatric patients treated with Amgen’s BiTE® immunotherapy added to chemotherapy will be presented during a plenary session at #ASH24, the American Society of Hematology’s annual meeting in San Diego on December 8 at 2:00 p.m. PT. 🔗 Press release: https://amgen.ly/3ZHZFXS